摘要
目的探讨血清铁蛋白在评估行高剂量少分次放疗Ⅲ期胰腺癌患者预后中的价值。方法初诊Ⅲ期胰腺癌患者39例,均采用高剂量少分次模式放疗,于放疗前行血清铁蛋白检测,并依据结果分为血清铁蛋白正常组27例与异常组12例,随访记录2组生存时间,并应用Log-rank检验进行比较。结果血清铁蛋白异常组中位生存时间11个月,正常组为21个月,Log-rank结果显示差异有统计学意义(P<0.05);中位生存时间在年龄、性别、初诊时体质量下降、KPS评分、肿瘤部位、血清糖类抗原19-9水平、放疗前是否行减黄或改道手术、是否伴区域淋巴结转移及同步化疗上差异无统计学意义(P>0.05)。结论Ⅲ期胰腺癌患者行高剂量少分次放疗前检测血清铁蛋白,可预测其生存时间。
Objective To investigate the value of serum ferritin to evaluating the prognosis of patients with stage III pancreatic cancer treated by high-dose hypo-fraction radiotherapy. Methods Thirty-nine patients with stage III pancreatic cancer were detected serum ferritin level before high-dose hypo-fraction chemotherapy, and were divided into normal ferritin group （n= 27） and abnormal ferritin group （n= 12） according to the ferritin level. The survival time was recorded and compared by Log-rank method between two groups. Results The median survival time was 11 months in normal ferritin group and 21 months in abnormal ferritin group, showing a significant difference by Log rank method （P〈0.05）. There were no significant differences in the median survival time in the age, gender, body mass decrease at the first visit, Karnofsky score, tumor location, carbohydrate antigen 19-9 level, surgical treatment before radiotherapy, regional lymph node metastasis and synchronous chemotherapy （P〈0.05）. Conclusion Serum ferritin can be used to predict the survival time of stage III pancreatic cancer before high-dose hypo-fraction radiotherapy.
出处
《中华实用诊断与治疗杂志》
2016年第2期184-186,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
首都卫生发展科研专项项目(2014-1-5124)
空军总医院面上课题(KZ2014037)
关键词
胰腺癌
铁蛋白
高剂量少分次放疗
预后
Pancreatic cancer
ferritin
high-close hypo-fraction radiotherapy
prognosis
